Life Biosciences is developing cellular rejuvenation therapies that target specific biological mechanisms of aging to reverse and prevent age-related diseases. Their approach aims to provide therapeutic options for chronic conditions that currently lack effective treatments.
Funding
$175.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AWFounders
Product
Problem
Aging is the primary risk factor for many chronic diseases, and a significant portion of the elderly population requires assistance with daily living activities. Current therapeutic options for age-related diseases are limited, creating a substantial unmet medical need.
Solution
Life Biosciences is developing cellular rejuvenation therapies that target the underlying biological mechanisms of aging to prevent and reverse age-related diseases. Their approach utilizes a partial epigenetic reprogramming platform, based on the science from world-leading researchers, to restore cellular function to a younger state. The company's lead program, ER-100, is a gene therapy that expresses transcription factors to induce partial epigenetic reprogramming. Life Biosciences is initially focusing on ocular indications, specifically non-arteritic anterior ischemic optic neuropathy (NAION) and primary open angle glaucoma (POAG), with plans to initiate human clinical studies. The company is also exploring the potential of its platform in additional age-related indications where epigenetic changes impact healthspan, developing delivery systems and demonstrating proof of concept in animal models.
Target Audience
The primary target audience includes individuals at risk of or affected by age-related diseases, as well as healthcare providers and researchers focused on extending healthy human lifespan.
Features
- Partial epigenetic reprogramming platform targeting key aging mechanisms
- ER-100 gene therapy candidate expressing Oct-4, Sox-2, and Klf-4 (OSK) transcription factors
- Focus on ocular indications, including NAION and POAG
- Development of delivery systems for OSK expression in various organ systems
- Preclinical studies in animal models to demonstrate proof of concept